Infinity Pharmaceuticals Inc. and Medimmune Inc. said Monday updated data from an early stage clinical trial of IPI-504 to treat gastrointestinal stromal tumors showed the drug cut the tumor's metabolic activity.
The updated results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The data showed that 44 percent of patients in the 18-person study showed a decrease in tumor uptake of 18-fluorodeoxyglucose, an imaging agent used to measure metabolic activity, that is, the tumor's distinctively elevated level of glucose absorption. The goal of the study, though, was to test safety and maximum tolerated dose.
Based on the results, the companies said they expanded the Phase I clinical trial. The results were first announced in November.
The updated results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The data showed that 44 percent of patients in the 18-person study showed a decrease in tumor uptake of 18-fluorodeoxyglucose, an imaging agent used to measure metabolic activity, that is, the tumor's distinctively elevated level of glucose absorption. The goal of the study, though, was to test safety and maximum tolerated dose.
Based on the results, the companies said they expanded the Phase I clinical trial. The results were first announced in November.
posted by doublezero at
8:02 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home